|Slideshows|May 28, 2021

What Is an SGM Community?

What terms are used to describe SGM and LGBTQ+ identities?

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Celebrating the First APA Panel of Transgender Psychiatrists of Color: A Conversation With Emrys Fonseca, MD, MS

ByEmrys Fonseca, MD, MS

June 25th 2026

Addressing Sexual Wellness: A Psychiatric Perspective

ByGrace L. Johnson, MD,Alex Rains, MD,Renee Sorrentino, MD

June 11th 2026

Sexual Health Assessment in Older Adults: Takeaways from APA

ByLea K. Marin, MD, MPH

May 21st 2026

Sexual Wellness in Older Adults With Anita Clayton, MD at APA

ByAnita H. Clayton, MD

May 19th 2026

Improving Care for LGBTQ+ and Immigrant Patients

ByUchenna Umeh, MD,Mich Gonzalez, JD

April 10th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

What Is an SGM Community?

Related Content

Celebrating the First APA Panel of Transgender Psychiatrists of Color: A Conversation With Emrys Fonseca, MD, MS

Addressing Sexual Wellness: A Psychiatric Perspective

Sexual Health Assessment in Older Adults: Takeaways from APA

Sexual Wellness in Older Adults With Anita Clayton, MD at APA

Improving Care for LGBTQ+ and Immigrant Patients

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Classic Drug, New Target: Lithium as Disease-Modifying in Alzheimer Dementia

The Psychiatric Impact of Cannabis Policy: More Than a Legal Framework

Remlifanserin for the Treatment of Alzheimer Disease Psychosis Receives FDA Fast Track Designation

Bipolar Disorder in Women of Childbearing Age: Proper Treatment Before Pregnancy

What's Next for Psychedelics in Psychiatry? COMP360 and Beyond